Metagenomi Therapeutics (MGX) Common Equity (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Common Equity of $137.8 million for Q1 2026, down 35.21% year-over-year from $212.7 million in Q1 2025, and down 13.12% quarter-over-quarter from $158.6 million in Q4 2025.
Metagenomi Therapeutics (MGX) Common Equity (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Common Equity for 4 consecutive years, with $137.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 35.21% year-over-year to $137.8 million; the TTM figure through Mar 2026 stood at $137.8 million (down 35.21% YoY), while the FY2025 annual figure was $158.6 million, down 32.47% from the prior year.
- Common Equity slipped to $137.8 million in Q1 2026 per MGX's latest filing, from $158.6 million in the prior quarter.
- Across five years, Common Equity topped out at $275.6 million in Q1 2024 and bottomed at -$135.6 million in Q4 2023.
- Historically, Common Equity has averaged $122.4 million across 4 years, with a median of $178.4 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity surged 214997.37% — and 2026, when it sank 35.21%.
- Metagenomi Therapeutics' Common Equity stood at -$135.6 million in 2023, then surged by 273.22% to $234.9 million in 2024, then sank by 32.47% to $158.6 million in 2025, then fell by 13.12% to $137.8 million in 2026.
- Business Quant data shows MGX's Common Equity at $137.8 million in Q1 2026, $158.6 million in Q4 2025, and $178.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 112.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112.57 Mn |
| Mar 31, 2026 | 137.79 Mn |
| Dec 31, 2025 | 158.60 Mn |
| Sep 30, 2025 | 178.45 Mn |
| Jun 30, 2025 | 195.83 Mn |
| Mar 31, 2025 | 212.66 Mn |
| Dec 31, 2024 | 234.86 Mn |
| Sep 30, 2024 | 255.77 Mn |
| Jun 30, 2024 | 269.42 Mn |
| Mar 31, 2024 | 275.63 Mn |
| Dec 31, 2023 | -135.58 Mn |
| Sep 30, 2023 | -119,021.00 |
| Jun 30, 2023 | -102.54 Mn |
| Mar 31, 2023 | -90.01 Mn |